Background:
This is the first study in humans testing a new drug called RO7502175. Researchers want to learn if it is safe, how the body processes it, and whether it can help shrink or control cancer.
The study includes people with several advanced or metastatic cancers—including kidney cancer (clear cell renal cell carcinoma) and urothelial carcinoma (cancer of the bladder, ureter, or kidney pelvis).
RO7502175 will be tested both on its own and together with approved immunotherapy drugs (atezolizumab or pembrolizumab), which help the immune system recognize and attack cancer cells.
The Trial:
This study is testing whether the new drug RO7502175, used alone or together with immunotherapy drugs (atezolizumab or pembrolizumab), is safe and effective at slowing down or shrinking advanced cancers such as kidney and urothelial cancer that have stopped responding to standard treatments.
There are several treatment groups in this study:
- RO7502175 alone (Phase Ia):
- Patients will first receive increasing doses of RO7502175 to find the safest amount.
- Once the right dose is found, more patients will receive the same dose to learn how well it works on its own.
- RO7502175 combined with immunotherapy (Phase Ib):
- In later groups, RO7502175 will be given together with an approved immunotherapy drug—either atezolizumab or pembrolizumab.
- These medicines help the immune system recognize and attack cancer cells.
- In later groups, RO7502175 will be given together with an approved immunotherapy drug—either atezolizumab or pembrolizumab.
This trial is not “blinded”, which means both you and your doctor will know which treatment you are receiving.
Basic Eligibility:
- Adults with advanced or metastatic cancer that cannot use standard treatments
- Must have a tumor that can be measured on scans
Additional eligibility criteria will apply. Please speak to your doctor.
| Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
|---|---|---|---|
| Hospital / Cancer CentreBritish Columbia Cancer Agency | Principal InvestigatorNot Given | LocationVancouver, BC | Trial StatusRecruiting |
| Hospital / Cancer CentreOttawa Hospital Regional Cancer Centre | Principal InvestigatorNot Given | LocationOttawa, ON | Trial StatusRecruiting |
| Hospital / Cancer CentrePrincess Margaret Cancer Centre | Principal InvestigatorNot Given | LocationToronto, ON | Trial StatusRecruiting |
| Hospital / Cancer CentreJewish General Hospital | Principal InvestigatorNot Given | LocationMontreal, ON | Trial StatusRecruiting |
